

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 November 2007 (01.11.2007)

PCT

(10) International Publication Number
WO 2007/124252 A3

(51) International Patent Classification:

A61K 31/132 (2006.01)	A61K 31/675 (2006.01)
A61K 31/136 (2006.01)	A61K 31/704 (2006.01)
A61K 31/282 (2006.01)	A61K 31/7068 (2006.01)
A61K 31/436 (2006.01)	A61K 31/7076 (2006.01)
A61K 31/437 (2006.01)	A61K 45/06 (2006.01)
A61K 31/475 (2006.01)	A61P 35/00 (2006.01)
A61K 31/5375 (2006.01)	A61P 35/02 (2006.01)
A61K 31/573 (2006.01)	

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BURKE, Gregory** [US/US]; 61 Heritage Court, Randolph, New Jersey 07869 (US). **LANE, Heidi** [CH/CH]; Jakobsweg 22, CH-4105 Biel-Benken (CH). **LINNARTZ, Ronald Richard** [US/US]; 42 Indian Trail, Andover, New Jersey 07821 (US). **VERSACE, Richard William** [US/US]; 69 Townsend Road, Wanaque, New Jersey 07465 (US).

(21) International Application Number:

PCT/US2007/066010

(22) International Filing Date: 5 April 2007 (05.04.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/789,400 5 April 2006 (05.04.2006) US

(71) Applicant (for all designated States except AT, US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant (for AT only): **NOVARTIS PHARMA GmbH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).


(74) Agent: **JACKSON, Oona A.**; Novartis, Corporate Intellectual Property, One Health Plaza Bldg. 104, East Hanover, NJ 07936-1080 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER



(57) Abstract: A combination of an mTOR inhibitor compound with one or more pharmaceutically active agents, for simultaneous, concurrent, separate or sequential use for preventing or treating a proliferative disease.

WO 2007/124252 A3



European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

Published:

— *with international search report*

(88) Date of publication of the international search report:

22 May 2008

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2007/066010

A. CLASSIFICATION OF SUBJECT MATTER INV. A61K31/132 A61K31/136 A61K31/282 A61K31/436 A61K31/437 A61K31/475 A61K31/5375 A61K31/573 A61K31/675 A61K31/704 A61K31/7068 A61K31/7076 A61K45/06 A61P35/00 A61P35/02				
According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) A61K A61P				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the International search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, CHEM ABS Data, MEDLINE, BIOSIS, EMBASE				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	WO 02/098416 A (WYETH CORP [US]) 12 December 2002 (2002-12-12) abstract page 1, line 3 - line 11 page 3, line 1 - line 12 page 8, line 28 - page 11, line 5 page 13, line 28 - page 14, line 9 claims 1-48 -----	1-14		
P,X	WO 2006/039414 A (ARIAD GENE THERAPEUTICS INC [US]; BEDROSIAN CAMILLE L [US]) 13 April 2006 (2006-04-13) page 2, line 20 - line 29 page 2, line 35 page 3, line 19 - line 26 claims 1-14 ----- -/--	1-14		
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none;"><input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C.</td> <td style="width: 50%; border: none;"><input checked="" type="checkbox"/> See patent family annex.</td> </tr> </table>			<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C.	<input checked="" type="checkbox"/> See patent family annex.
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C.	<input checked="" type="checkbox"/> See patent family annex.			
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none;"> * Special categories of cited documents : *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 50%; border: none;"> *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *Z* document member of the same patent family </td> </tr> </table>			* Special categories of cited documents : *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *Z* document member of the same patent family
* Special categories of cited documents : *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *Z* document member of the same patent family			
Date of the actual completion of the international search <p style="text-align: center;">4 February 2008</p>	Date of mailing of the international search report <p style="text-align: center;">31/03/2008</p>			
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer <p style="text-align: center;">Taylor, Mark</p>			

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2007/066010

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>WO 2006/065780 A (NOVARTIS AG [CH]; NOVARTIS PHARMA GMBH [AT]; SIGMA TAU IND FARMACEUTI) 22 June 2006 (2006-06-22) abstract page 2 page 6, line 20 - line 26 page 13, line 7 - line 14 example 11 claims 1-22</p>	1-14
E	<p>WO 2007/056118 A (WYETH CORP [US]; MOORE LAURENCE [US]; ZACHARCHUK CHARLES [US]; RABINDR) 18 May 2007 (2007-05-18) abstract page 3, line 11 - line 22 page 4, line 3 - page 6, line 12 examples 1-3 page 27, line 13 - line 21 claims 1-44</p>	1-14
A	<p>RECHER, C; DOS SANTOS, C; DEMUR, C; PAYRASTRE, B: "mTOR, a new therapeutic target in acute myeloid leukemia" CELL CYCLE, vol. 4, no. 11, 2005, pages 1538-1547, XP002467483 the whole document</p>	1-14
E	<p>WO 2007/057457 A (NOVARTIS AG [CH]; NOVARTIS PHARMA GMBH [AT]; MARKS PETER WAYNE [US]; L) 24 May 2007 (2007-05-24) abstract page 1, line 3 - page 3, line 8 page 9, line 29 - page 10, line 22 page 12, line 28 - page 14, line 27 page 16, line 25 - page 31, line 31 page 32, line 5 - page 34, line 11 page 37, line 7 claims 1-12</p>	1-14
E	<p>WO 2007/106503 A (OSI PHARM INC; BUCK ELIZABETH A [US]; GRIFFIN GRAEME [US]; BARR SHARON) 20 September 2007 (2007-09-20) abstract paragraph [0019] - paragraph [0024] paragraph [0546] - paragraph [0559] claims 1-64</p>	1-14

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2007/066010

Patent document cited in search report	A	Publication date		Patent family member(s)	Publication date
WO 02098416	A	12-12-2002		BR 0210101 A	08-06-2004
				CA 2447732 A1	12-12-2002
				CN 1646120 A	27-07-2005
				EP 1392286 A2	03-03-2004
				HU 0400006 A2	28-04-2004
				JP 2004532883 T	28-10-2004
				MX PA03010907 A	17-02-2004
				NO 20035317 A	22-12-2003
				NZ 529877 A	19-12-2003
				PL 367267 A1	21-02-2005
<hr style="border-top: 1px dashed black;"/>					
WO 2006039414	A	13-04-2006		AU 2005292033 A1	13-04-2006
				CA 2581372 A1	13-04-2006
				EP 1809276 A2	25-07-2007
<hr style="border-top: 1px dashed black;"/>					
WO 2006065780	A	22-06-2006		AU 2005316652 A1	22-06-2006
				CA 2589521 A1	22-06-2006
				CN 101080227 A	28-11-2007
				EP 1827437 A2	05-09-2007
				KR 20070091286 A	10-09-2007
<hr style="border-top: 1px dashed black;"/>					
WO 2007056118	A	18-05-2007	AR	057854 A1	19-12-2007
<hr style="border-top: 1px dashed black;"/>					
WO 2007057457	A	24-05-2007	NONE		
<hr style="border-top: 1px dashed black;"/>					
WO 2007106503	A	20-09-2007	US	2007280928 A1	06-12-2007
<hr style="border-top: 1px dashed black;"/>					